EDN1 and diabetes mellitus: Other studies have demonstrated a reduction in ET-1 serum levels in patients with diabetes undergoing TMZ treatment, both after short-term (2 weeks) and long-term (6 months) therapy; however, no decrease was detected in the placebo group [4, 17].